Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2019

27.10.2018 | Original Article

Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors

verfasst von: Moritz von Wulffen, Nicholas J. Talley, Johann Hammer, Jessica McMaster, Graeme Rich, Ayesha Shah, Natasha Koloski, Bradley J. Kendall, Mike Jones, Gerald Holtmann

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

According to Rome IV criteria, functional dyspepsia (FD) and irritable bowel syndrome (IBS) are distinct functional gastrointestinal disorders (FGID); however, overlap of these conditions is common in population-based studies, but clinical data are lacking.

Aims

To determine the overlap of FD and IBS in the clinical setting and define risk factors for the overlap of FD/IBS.

Methods

A total of 1127 consecutive gastroenterology outpatients of a tertiary center were recruited and symptoms assessed with a standardized validated questionnaire. Patients without evidence for structural or biochemical abnormalities as a cause of symptoms were then categorized based upon the symptom pattern as having FD, IBS or FD/IBS overlap. Additionally, this categorization was compared with the clinical diagnosis documented in the integrated electronic medical records system.

Results

A total of 120 patients had a clinical diagnosis of a FGID. Based upon standardized assessment with a questionnaire, 64% of patients had FD/IBS overlap as compared to 23% based upon the routine clinical documentation. In patients with severe IBS or FD symptoms (defined as symptoms affecting quality of life), the likelihood of FD/IBS overlap was substantially increased (OR = 3.1; 95%CI 1.9–5.0) and (OR = 9.0; 95%CI 3.5–22.7), respectively. Thus, symptom severity for IBS- or FD symptoms were significantly higher for patients with FD/IBS overlap as compared to patients with FD or IBS alone (p all < 0.01). Age, gender and IBS-subtype were not associated with overlap.

Conclusion

In the clinical setting, overlap of FD and IBS is the norm rather than the exception. FD/IBS overlap is associated with a more severe manifestation of a FGID.
Literatur
1.
Zurück zum Zitat Rome Foundation. Guidelines–Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:307–12. Rome Foundation. Guidelines–Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:307–12.
2.
Zurück zum Zitat Keely S, Walker MM, Marks E, et al. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest. 2015;45:1350–1359.CrossRefPubMed Keely S, Walker MM, Marks E, et al. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest. 2015;45:1350–1359.CrossRefPubMed
4.
Zurück zum Zitat El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther. 2004;19:643–654.CrossRefPubMed El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther. 2004;19:643–654.CrossRefPubMed
5.
Zurück zum Zitat Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949–958.CrossRefPubMed Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949–958.CrossRefPubMed
6.
Zurück zum Zitat Talley NJ. Scope of the problem of functional digestive disorders. Eur J Surg Suppl. 1998;164(S12):35–41. Talley NJ. Scope of the problem of functional digestive disorders. Eur J Surg Suppl. 1998;164(S12):35–41.
7.
Zurück zum Zitat Icks A, Haastert B, Enck P, et al. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol. 2002;40:177–183.CrossRefPubMed Icks A, Haastert B, Enck P, et al. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol. 2002;40:177–183.CrossRefPubMed
8.
Zurück zum Zitat Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20:31–39.CrossRefPubMed Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20:31–39.CrossRefPubMed
9.
Zurück zum Zitat Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol. 2002;97:2290–2299.CrossRef Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol. 2002;97:2290–2299.CrossRef
10.
Zurück zum Zitat Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointestin Liver Physiol. 2012;303:G775–G785.CrossRef Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointestin Liver Physiol. 2012;303:G775–G785.CrossRef
11.
Zurück zum Zitat Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63:262–271.CrossRefPubMed Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63:262–271.CrossRefPubMed
13.
Zurück zum Zitat Gwee KA, Chua AS. Functional dyspepsia and irritable bowel syndrome, are they different entities and does it matter? World J Gastroenterol. 2006;12:2708–2712.CrossRefPubMedPubMedCentral Gwee KA, Chua AS. Functional dyspepsia and irritable bowel syndrome, are they different entities and does it matter? World J Gastroenterol. 2006;12:2708–2712.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122:107–112.CrossRefPubMed Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med. 1995;122:107–112.CrossRefPubMed
15.
Zurück zum Zitat Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660.CrossRefPubMed Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660.CrossRefPubMed
16.
Zurück zum Zitat Wang YT, Lim HY, Tai D, et al. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 2012;12:104.CrossRefPubMedPubMedCentral Wang YT, Lim HY, Tai D, et al. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 2012;12:104.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol. 2006;30:241–246.CrossRefPubMed Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol. 2006;30:241–246.CrossRefPubMed
18.
Zurück zum Zitat Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol. 2000;95:67–71.CrossRefPubMed Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol. 2000;95:67–71.CrossRefPubMed
19.
Zurück zum Zitat Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007.CrossRefPubMed Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999–1007.CrossRefPubMed
20.
Zurück zum Zitat Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903–912.CrossRefPubMed Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903–912.CrossRefPubMed
21.
Zurück zum Zitat Rey E, Garcia-Alonso MO, Moreno-Ortega M, et al. Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol. 2008;42:1003–1009.CrossRefPubMed Rey E, Garcia-Alonso MO, Moreno-Ortega M, et al. Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol. 2008;42:1003–1009.CrossRefPubMed
22.
Zurück zum Zitat Holz H, Koloski NA, Jones MP, et al. Su1015 the validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for use in the clinical setting. Gastroenterology. 2016;150:444.CrossRef Holz H, Koloski NA, Jones MP, et al. Su1015 the validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for use in the clinical setting. Gastroenterology. 2016;150:444.CrossRef
24.
Zurück zum Zitat Layer P, Andresen V, Pehl C, et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011;49:237–293.CrossRefPubMed Layer P, Andresen V, Pehl C, et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol. 2011;49:237–293.CrossRefPubMed
25.
Zurück zum Zitat Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–1279.CrossRef Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–1279.CrossRef
26.
Zurück zum Zitat Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.CrossRefPubMed Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.CrossRefPubMed
27.
Zurück zum Zitat Whitehead WE, Gibbs NA, Li Z, et al. Is functional dyspepsia just a subset of the irritable bowel syndrome? Baillieres Clin Gastroenterol. 1998;12:443–461.CrossRefPubMed Whitehead WE, Gibbs NA, Li Z, et al. Is functional dyspepsia just a subset of the irritable bowel syndrome? Baillieres Clin Gastroenterol. 1998;12:443–461.CrossRefPubMed
28.
Zurück zum Zitat Corsetti M, Caenepeel P, Fischler B, et al. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004;99:1152–1159.CrossRefPubMed Corsetti M, Caenepeel P, Fischler B, et al. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol. 2004;99:1152–1159.CrossRefPubMed
29.
Zurück zum Zitat Hammer J, Talley NJ. Disturbed bowel habits in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2006;24:405–410.CrossRefPubMed Hammer J, Talley NJ. Disturbed bowel habits in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2006;24:405–410.CrossRefPubMed
30.
Zurück zum Zitat Aziz I, Palsson OS, Törnblom H, et al. The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a crosssectional general population study in three countries. Am J Gastroenterol. 2018;113(1):86.CrossRefPubMed Aziz I, Palsson OS, Törnblom H, et al. The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a crosssectional general population study in three countries. Am J Gastroenterol. 2018;113(1):86.CrossRefPubMed
31.
Zurück zum Zitat Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107:1793–1801. (quiz 1802).CrossRefPubMed Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol. 2012;107:1793–1801. (quiz 1802).CrossRefPubMed
32.
Zurück zum Zitat Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2016;150:1469–1480.e1.CrossRefPubMed Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2016;150:1469–1480.e1.CrossRefPubMed
33.
Zurück zum Zitat Frank L, Kleinman L, Rentz A, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24:675–689. (discussion 674).CrossRefPubMed Frank L, Kleinman L, Rentz A, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24:675–689. (discussion 674).CrossRefPubMed
34.
Zurück zum Zitat Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166:85–90.CrossRefPubMed Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166:85–90.CrossRefPubMed
35.
Zurück zum Zitat El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3:S3–S11.PubMed El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3:S3–S11.PubMed
36.
Zurück zum Zitat Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther. 1997;11:553–559.CrossRefPubMed Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther. 1997;11:553–559.CrossRefPubMed
Metadaten
Titel
Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors
verfasst von
Moritz von Wulffen
Nicholas J. Talley
Johann Hammer
Jessica McMaster
Graeme Rich
Ayesha Shah
Natasha Koloski
Bradley J. Kendall
Mike Jones
Gerald Holtmann
Publikationsdatum
27.10.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5343-6

Weitere Artikel der Ausgabe 2/2019

Digestive Diseases and Sciences 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.